Manila Times Business
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik®(tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk profile of pociredir in sickle cell disease (SCD) ― ― Company to explore strategic alternatives to maximize stockholder value ― CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small m
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Guggenheim Investments Announces June 2026 Closed-End Fund Distributions
1h ago
University of Miami Miller School of Medicine Names Dr. Pradeep Ramulu Chair of Ophthalmology and the Bascom Palmer Eye Institute
1h ago
Xometry Announces Proposed Public Offering of Class A Common Stock
1h ago
Hallador Energy Acquires 460 MW of Siemens Turbines for $350 Million, Accelerating Merom Natural Gas Generation Project
1h ago